Presented at 2025 SABCS, the phase III lidERA trial showed that oral SERD giredestrant reduced the risk of invasive disease ...

Arcellx’s Phase 2 iMMagine 1 trial of anito cel in heavily pretreated multiple myeloma delivered a 96% response rate, 74% ...

New clinical data presented at the 67th ASH Annual Meeting indicated that Lunsumio could be a strong candidate for earlier ...

Early findings from the FANSS study, presented at ESMO Asia 2025, point to a potential shift in how clinicians identify lung ...

Early Phase 1b data for enozertinib, presented at the ESMO Asia Congress 2025, show strong systemic and intracranial activity ...

Harvard scientists have defined the exact DNA cross-link created by colibactin, a gut microbial toxin associated with ...

Scientists have demonstrated an automated bioreactor system that produces large numbers of human lung organoids. The ...

Researchers have developed intranasal spherical nucleic acids that activate the cGAS–STING pathway and reprogram the ...

The FDA has approved pembrolizumab (Keytruda) or pembrolizumab Qlex with enfortumab vedotin (Padcev) as the first ...

ONCOLife as a cutting-edge oncology magazine designed for oncologists and health professionals. It has flexible format, available both in print and online formats in the US and EU, ONCOLife is ...

A new PNAS study unveils a hidden vulnerability of prostate cancer: the protein-disulfide isomerases PDIA1 and PDIA5, which stabilize androgen receptor and sustain tumor survival. Inhibition of these ...